151 related articles for article (PubMed ID: 23711895)
1. Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study.
Dolling DI; Dunn DT; Sutherland KA; Pillay D; Mbisa JL; Parry CM; Post FA; Sabin CA; Cane PA; ;
J Antimicrob Chemother; 2013 Oct; 68(10):2339-43. PubMed ID: 23711895
[TBL] [Abstract][Full Text] [Related]
2. Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).
Lambert-Niclot S; Grude M; Chaix ML; Charpentier C; Reigadas S; Le Guillou-Guillemette H; Rodallec A; Amiel C; Maillard A; Dufayard J; Mourez T; Mirand A; Guinard J; Montes B; Vallet S; Marcelin AG; Descamps D; Flandre P; Delaugerre C; Morand-Joubert L;
J Antimicrob Chemother; 2018 Aug; 73(8):2147-2151. PubMed ID: 29718247
[TBL] [Abstract][Full Text] [Related]
3. No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.
Perrier M; Visseaux B; Landman R; Joly V; Todesco E; Yazdanpanah Y; Calvez V; Marcelin AG; Descamps D; Charpentier C
J Antimicrob Chemother; 2018 Jan; 73(1):173-176. PubMed ID: 29077926
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
Gianotti N; Seminari E; Guffanti M; Boeri E; Villani P; Regazzi M; Bigoloni A; Schira G; Tiberi S; Fusetti G; Lazzarin A; Castagna A
New Microbiol; 2005 Apr; 28(2):119-25. PubMed ID: 16035256
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients.
Bonora S; Calcagno A; Vigano O; Bigliano P; Marinaro L; Colella E; Orofino G; Trentini L; Tettoni MC; D'Avolio A; Mercadante S; Galli M; Di Perri G; Rusconi S
Curr HIV Res; 2014; 12(5):339-46. PubMed ID: 25106410
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.
Mollan K; Daar ES; Sax PE; Balamane M; Collier AC; Fischl MA; Lalama CM; Bosch RJ; Tierney C; Katzenstein D;
J Infect Dis; 2012 Dec; 206(12):1920-30. PubMed ID: 23148287
[TBL] [Abstract][Full Text] [Related]
7. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
[TBL] [Abstract][Full Text] [Related]
8. The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.
Martinez-Cajas JL; Wainberg MA; Oliveira M; Asahchop EL; Doualla-Bell F; Lisovsky I; Moisi D; Mendelson E; Grossman Z; Brenner BG
J Antimicrob Chemother; 2012 Apr; 67(4):988-94. PubMed ID: 22315096
[TBL] [Abstract][Full Text] [Related]
9. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
[TBL] [Abstract][Full Text] [Related]
10. External validation of atazanavir/ritonavir genotypic score in HIV-1 protease inhibitor-experienced patients.
Marcelin AG; Chazallon C; Gérard L; Saïdi Y; Aboulker JP; Girard PM; Calvez V; Piketty C
J Acquir Immune Defic Syndr; 2006 May; 42(1):127-8. PubMed ID: 16639354
[No Abstract] [Full Text] [Related]
11. Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure.
Dumans AT; Barreto CC; Santos AF; Arruda M; Sousa TM; Machado ES; Sabino EC; Brindeiro RM; Tanuri A; Duarte AJ; Soares MA
Infect Genet Evol; 2009 Jan; 9(1):62-70. PubMed ID: 18992847
[TBL] [Abstract][Full Text] [Related]
12. Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis.
Mata-Munguía C; Escoto-Delgadillo M; Torres-Mendoza B; Flores-Soto M; Vázquez-Torres M; Gálvez-Gastelum F; Viniegra-Osorio A; Castillero-Manzano M; Vázquez-Valls E
BMC Bioinformatics; 2014 Mar; 15():72. PubMed ID: 24629078
[TBL] [Abstract][Full Text] [Related]
13. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.
Tinago W; O'Halloran JA; O'Halloran RM; Macken A; Lambert JS; Sheehan GJ; Mallon PW
HIV Med; 2014 Apr; 15(4):224-32. PubMed ID: 24215370
[TBL] [Abstract][Full Text] [Related]
14. Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.
Lataillade M; Chiarella J; Yang R; DeGrosky M; Uy J; Seekins D; Simen B; St John E; Moreno E; Kozal M
PLoS One; 2012; 7(2):e30118. PubMed ID: 22355307
[TBL] [Abstract][Full Text] [Related]
15. Mutations selected in HIV-2-infected patients failing a regimen including atazanavir.
Cavaco-Silva J; Aleixo MJ; Van Laethem K; Faria D; Valadas E; Gonçalves Mde F; Gomes P; Vandamme AM; Cunha C; Camacho RJ;
J Antimicrob Chemother; 2013 Jan; 68(1):190-2. PubMed ID: 22977160
[TBL] [Abstract][Full Text] [Related]
16. Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50.
Mittal S; Bandaranayake RM; King NM; Prabu-Jeyabalan M; Nalam MN; Nalivaika EA; Yilmaz NK; Schiffer CA
J Virol; 2013 Apr; 87(8):4176-84. PubMed ID: 23365446
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens.
Santos JR; Llibre JM; Imaz A; Domingo P; Iribarren JA; Mariño A; Miralles C; Galindo MJ; Ornelas A; Moreno S; Schapiro JM; Clotet B;
J Antimicrob Chemother; 2012 Jun; 67(6):1462-9. PubMed ID: 22431669
[TBL] [Abstract][Full Text] [Related]
18. Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients.
Marcelin AG; Masquelier B; Descamps D; Izopet J; Charpentier C; Alloui C; Bouvier-Alias M; Signori-Schmuck A; Montes B; Chaix ML; Amiel C; Santos GD; Ruffault A; Barin F; Peytavin G; Lavignon M; Flandre P; Calvez V
Antimicrob Agents Chemother; 2008 Sep; 52(9):3237-43. PubMed ID: 18625773
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.
Yanchunas J; Langley DR; Tao L; Rose RE; Friborg J; Colonno RJ; Doyle ML
Antimicrob Agents Chemother; 2005 Sep; 49(9):3825-32. PubMed ID: 16127059
[TBL] [Abstract][Full Text] [Related]
20. Predictors of virological response to atazanavir in protease inhibitor-experienced patients.
Barrios A; Rendón AL; Gallego O; Martín-Carbonero L; Valer L; Ríos P; Maida I; García-Benayas T; Jiménez-Nácher I; González-Lahoz J; Soriano V
HIV Clin Trials; 2004; 5(4):201-5. PubMed ID: 15472794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
